This tailored review assesses the efficacy, safety, and cost associated with the SC form of biosimilar infliximab (Remsima SC, with a NOC status of completed on January 28, 2021) for the treatment of patients with RA. The new formulation consists of a solution for SC administration (120 mg/mL) in a 1 mL pre-filled syringe. Remsima SC is expected to be the first SC formulation of infliximab, aimed at patients who are initiating infliximab therapy (maintenance after 2 IV doses) or who are currently receiving infliximab IV maintenance therapy and are suitable to be switched to the SC formulation. The potential advantage for patients is a formulation that can be easily self-administered at home — of particular interest in the current COVID-19 pandemic — with better preparation time, patient convenience, and adherence, resulting in optimization of medical resources.